Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers

The updated findings, derived from an expanded cohort, further support the adoption of durvalumab in combination with gemcitabine and cisplatin in routine clinical practice, reinforcing the efficacy and safety outcomes demonstrated in the phase III TOPAZ-1 trial.

Authors

Institutions

Publication Details

Journal
Liver International
Published
2025-11-12
DOI
https://doi.org/10.1111/liv.70428
Citations
4
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
8.03

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers

Nuno Couto, Emanuela Dell’Aquila, David James Pinato, Lorenzo Antonuzzo et al.
4 citations
Liver International
Cholangiocarcinoma and Gallbladder Cancer Studies
8.03
article

Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers

Nuno Couto, Emanuela Dell’Aquila, David James Pinato, Lorenzo Antonuzzo, Silvia Camera, Michele Ghidini, Stefano Tamberi, Alessandra Anna Prete, Tiziana Pressiani, Elisabetta Fenocchio, Monica Verrico, Oluseyi Abidoye, Francesca Salani, Emiliano Tamburini, Margherita Rimini, Masafumi Ikeda, Anna Lena Saborowski, Alessandro Pastorino, Lucrezia Zumstein, Alessandro Parisi, Monica Niger, Mara Persano, Gerald W. Prager, Lukas Perkhofer, Lorenzo Fornaro, Giovanni Farinea, Caterina Vivaldi, Florian Castet, C. Pinto, Gian Paolo Spinelli, Min-Su Kang, Ilario Giovanni Rapposelli, Michele Ferrara, Mario Scartozzi, Matteo Landriscina, Stephen L. Chan, Chiara Braconi, Marta Schirripa, Anna Diana, Jessica Lucchetti, Sara Lonardi, Laura Passeri, Gianluca Masi, Maria Grazia Rodriquenz, Ester Oneda, Lorenza Rimassa, Hong Jae Chon, Salvatore Corallo, Ingrid Garajová, Daniele Lavacchi, Chiara Pircher, Federico Nichetti, Beodeul KANG, Tanios Bekaii‐Saab, Silvia Bozzarelli, Emily Warmington, Tomoyuki Satake, Rita Balsano, Frederik Peeters, Ángela Lamarca, Andrea Casadei‐Gardini, Antonio Avallone, Giuseppe Aprile, Changhoon Yoo, A. Martirena, Jin Won Kim, Il Hwan Kim, Arndt Vogel, Alessia Lancianese, Fabian Fimkelmeier, Su Yung‐Yeh
article en
4 citations

Abstract

The updated findings, derived from an expanded cohort, further support the adoption of durvalumab in combination with gemcitabine and cisplatin in routine clinical practice, reinforcing the efficacy and safety outcomes demonstrated in the phase III TOPAZ-1 trial.

Liver InternationalVol. 45(12)
University of Pisa (IT), Champalimaud Foundation (PT), Goethe University Frankfurt (DE), Marche Polytechnic University (IT), Hebron University (PS), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), University of Parma (IT), Humanitas University (IT), Vita-Salute San Raffaele University (IT), National Health Research Institutes (TW), University of Cagliari (IT), Chinese University of Hong Kong (HK), University of Pavia (IT), Cardinal Health (Australia) (AU), Casa Sollievo della Sofferenza (IT), Policlinico Umberto I (IT), Beatson West of Scotland Cancer Centre (GB), Hammersmith Hospital (GB), Princess Margaret Cancer Centre (CA), Seoul National University Bundang Hospital (KR), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Medizinische Hochschule Hannover (DE), University of Ulsan (KR), Ospedali Riuniti di Foggia (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Hospital Universitario 12 De Octubre (ES), Inje University Haeundae Paik Hospital (KR), Istituto Oncologico Veneto (IT), Administração Regional de Saúde de Lisboa e Vale do Tejo (PT), University Hospitals Parma Medical Center (US), Prince of Wales Hospital (CN), Azienda Ospedaliero-Universitaria Careggi (IT), Algarve Biomedical Center (PT), Mayo Clinic in Arizona (US), Ospedale di Belcolle (IT), Hospital Universitario Fundación Jiménez Díaz (ES), University Hospital Frankfurt (DE), CHA University Bundang Medical Center (KR), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Campus Bio Medico University Hospital (IT), National Cancer Center Hospital East (JP), Tumori Foundation (US), Ospedale Policlinico San Martino (IT), Fondazione Poliambulanza Istituto Ospedaliero (IT), Ospedale D. Cotugno (IT), Candiolo Cancer Institute (IT), Policlinico San Matteo Fondazione (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), University Hospital Ulm (DE), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), National Cheng Kung University Hospital (TW), International Renal Research Institute of Vicenza (IT), IRCCS Humanitas Research Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), University of Florence (IT), Imperial College London (GB), University of Turin (IT), Universidad Autónoma de Madrid (ES), University of Algarve (PT), Medical University of Vienna (AT), University of Bologna (IT)
Seoul National University Bundang Hospital, Seoul National University, Università degli Studi di Firenze, Medizinischen Hochschule Hannover, Istituto Oncologico Veneto, College of Medicine, Seoul National University, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze
Openalex Percentile: Top 2%
Cholangiocarcinoma and Gallbladder Cancer Studies
8.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.